Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Chemotherapy (DDGP vs VIPD) Followed Radiotherapy Vs Radiotherapy Followed Chemotherapy (DDGP vs VIPD) Vs Radiotherapy Alone for Newly Diagnosed Early Stage Extranodal Natural Killer/T Cell Lymphoma: Final Results of a Prospective, Multicenter, Randomized, Controlled Clinical Trial

Mingzhi Zhang, Lei Zhang, Xin Li, Ling Li, Xinhua Wang, Xiaorui Fu, Zhenchang Sun, Yu Chang, Xudong Zhang, Hui Yu, Feifei Nan, Zhiyuan Zhou, Xiyang Liu, Xiaolong Wu, Liqun Zou, Hui Zhou, Hongwei Xue

Blood (2023) 142 (Supplement 1): 1690.

https://doi.org/10.1182/blood-2023-188245

Published: 2023

Journal Articles

Phase I Clinical Study of PA3-17 Injection in Patients with Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma

Blood (2023) 142 (Supplement 1): 3471.

https://doi.org/10.1182/blood-2023-178484

Published: 2023

Journal Articles

A Phase I/II Study of Orelabrutinib Combined with Anti-Programmed Cell Death Protein-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)

Xudong Zhang, Wenhua Wang, Shanshan Ma, Mengke Fan, Linan Zhu, Lei Zhang, Xin Li, Ling Li, Zhenchang Sun, Xinhua Wang, Xiaorui Fu, Zhaoming Li, Jiaqin Yan, Mingzhi Zhang

Blood (2022) 140 (Supplement 1): 12075–12076.

https://doi.org/10.1182/blood-2022-159383

Published: 2022

Journal Articles

Analysis of the Tumor Microenvironment By Quantitative Immunohistochemistry Reveals Novel Predictors in Classic Hodgkin Lymphoma Treated with Anti-PD1 Therapy

Hui Yu, Jiali Ni, Zhenchang Sun, Mingzhi Zhang

Blood (2021) 138 (Supplement 1): 4530.

https://doi.org/10.1182/blood-2021-152666

Published: 2021

Journal Articles

The Impact of the Immunophenotyping Characteristics of Patients' Peripheral Blood on the Manufacturing and Clinical Outcome of CD7-Targeted Chimeric Antigen Receptor T Cells

Blood (2021) 138 (Supplement 1): 3830.

https://doi.org/10.1182/blood-2021-147632

Published: 2021

Journal Articles

A Single-Arm, Open-Label, Pilot Trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma

Blood (2021) 138 (Supplement 1): 3829.

https://doi.org/10.1182/blood-2021-149999

Published: 2021

Journal Articles

Anti-PD-1-Antibody (Tislelizumab) Combined with Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory/Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial

Lei Zhang, Xiyang Liu, Xinhua Wang, Yu Chang, Xiaorui Fu, Xin Li, Ling Li, Jiaqin Yan, Feifei Nan, Xiaolong Wu, Linan Zhu, Zhenchang Sun, Hui Yu, Mingzhi Zhang

Blood (2021) 138 (Supplement 1): 1368.

https://doi.org/10.1182/blood-2021-152020

Published: 2021

Journal Articles

Fotemustine-Based in Combination with Rituximab As First-Line Induction Chemotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma:a Prospective Phaseii Trial

Blood (2020) 136 (Supplement 1): 5.

https://doi.org/10.1182/blood-2020-137449

Published: 2020

Journal Articles

Activating NOTCH1 Mutations Alter T-ALL Chemosensitivity By PREX2-AKT Pathway

Hui Yu, MD, PhD, Yuxin DU, MD, M.S., Ji Xu, MD, PhD, Zhenchang Sun, MD, PhD, Xiaorui Fu, MD, PhD, Ken H. Young, MD, PhD, Mingzhi Zhang, MD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-138665

Published: 2020

Journal Articles

Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen

Blood (2019) 134 (Supplement_1): 463.

https://doi.org/10.1182/blood-2019-127811

Published: 2019

Journal Articles

Efficacy and Safety of Novel Targeted Drug' Apatinib in Relapse or Refractory Non-Hodgkin Lymphoma: An Open Label, Single-Armed, Exploratory Study

Ling Li, MSPH, Sa Xiao, Ken H. Young, MD PhD, Lei Zhang, MD, Xin Li, MD, Xiaorui Fu, MDPhD, Zhaoming Li, MDPhD, Zhenchang Sun, MDPhD, Xudong Zhang, MDPhD, Jiaqin Yan, MDPhD, Feifei Nan, MDPhD, Yu Chang, Mengyuan Shi, graduate student, Mingzhi Zhang

Blood (2017) 130 (Supplement 1): 1548.

https://doi.org/10.1182/blood.V130.Suppl_1.1548.1548

Published: 2017

Journal Articles

Primary Testicular Lymphoma:a Single Center Experience and Literature Review

Ling Li, MDPhD, Fangwen Zhang, graduate student, Ken H. Young, MD PhD, Wenjing Duan, graduate student, Zhaoming Li, MD PhD, Jiaqin Yan, MD PhD, Xiaorui Fu, MD PhD, Lei Zhang, MD PhD, Xin Li, MD PhD, Zhenchang Sun, MD PhD, Xudong Zhang, MD PhD, Yu Chang, MD, Feifei Nan, MD PhD, Mingzhi Zhang, MD PhD

Blood (2016) 128 (22): 5415.

https://doi.org/10.1182/blood.V128.22.5415.5415

Published: 2016

Journal Articles

GDPT Versus CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma: A Prospective Randomized Controlled, Open-Label Study (No.NCT01664975)

Ling Li, MD PhD, Wenjing Duan, graduate student, Ken H. Young, MD PhD, Zhaoming Li, MD PhD, Lei Zhang, MD PhD, Xiaorui Fu, MD PhD, Xin Li, MD PhD, Zhenchang Sun, MD PhD, Xudong Zhang, MD PhD, Jiaqin Yan, MD PhD, Feifei Nan, MD PhD, Yu Chang, MD, Li Lin, MD, Mingzhi Zhang, MD PhD

Blood (2016) 128 (22): 2989.

https://doi.org/10.1182/blood.V128.22.2989.2989

Published: 2016

NARROW

Phase I Clinical Study of PA3-17 Injection in Patients with Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma

A Phase I/II Study of Orelabrutinib Combined with Anti-Programmed Cell Death Protein-1 Antibody and Fotemustine for Patients with Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL)

Analysis of the Tumor Microenvironment By Quantitative Immunohistochemistry Reveals Novel Predictors in Classic Hodgkin Lymphoma Treated with Anti-PD1 Therapy

The Impact of the Immunophenotyping Characteristics of Patients' Peripheral Blood on the Manufacturing and Clinical Outcome of CD7-Targeted Chimeric Antigen Receptor T Cells

A Single-Arm, Open-Label, Pilot Trial of Autologous CD7-CAR-T Cells for CD7 Positive Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma

Anti-PD-1-Antibody (Tislelizumab) Combined with Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory/Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial

Fotemustine-Based in Combination with Rituximab As First-Line Induction Chemotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma:a Prospective Phaseii Trial

Activating NOTCH1 Mutations Alter T-ALL Chemosensitivity By PREX2-AKT Pathway

Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen

Efficacy and Safety of Novel Targeted Drug' Apatinib in Relapse or Refractory Non-Hodgkin Lymphoma: An Open Label, Single-Armed, Exploratory Study

Primary Testicular Lymphoma:a Single Center Experience and Literature Review

GDPT Versus CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma: A Prospective Randomized Controlled, Open-Label Study (No.NCT01664975)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only